AGN-232411
DrugAGN-232411 topical ophthalmic solution
NCT Number: NCT02420730
This study will examine the safety, tolerability, and systemic pharmacokinetics of up to 3 different concentrations of AGN-232411 topical ophthalmic solution in healthy participants and participants with dry eye.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Sall Research Center, Artesia, California, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Stage 1
-Healthy participants.
Stage 2 -Participants with the symptoms of dry eye disease.
Exclusion criteria
Stage 1
-Known allergies or sensitivities to study medications, fluorescein, or lissamine green
Stage 2
AGN-232411 topical ophthalmic solution
Vehicle for AGN-232411 topical ophthalmic solution.
Time frame: Up to 56 days
Allergan
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00862433
Body Weight, Diabetes
Bethesda, Maryland, United States
View Trial DetailsNCT00001471
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Bethesda, Maryland, United States
View Trial DetailsNCT00353158
Bacterial Infections, Bacterial Infections and Mycoses
Bethesda, Maryland, United States
View Trial DetailsNCT07760389
Healthy Volunteers
Nicosia, Lefkosa, Cyprus
View Trial Details